New Zealand markets close in 4 hours 40 minutes

CEL-SCI Corporation (CVM)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
4.1700+0.1700 (+4.25%)
At close: 04:00PM EDT
4.2400 +0.07 (+1.68%)
After hours: 04:57PM EDT

CEL-SCI Corporation

8229 Boone Boulevard
Suite 802
Vienna, VA 22182
United States
703 506 9460

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Geert R. Kersten Esq.Chief Exec. & Financial Officer, Treasurer and Director635.65kN/A1959
Ms. Patricia B. PrichepSr. VP of Operations & Corp. Sec.270.05kN/A1951
Dr. Eyal Talor Ph.D.Chief Scientific Officer320.86kN/A1956
Dr. Daniel H. Zimmerman Ph.D.Sr. VP of Research & Cellular Immunology249.01kN/A1941
Mr. John CiprianoSr. VP of Regulatory Affairs225.36kN/A1942
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Corporate governance

CEL-SCI Corporation’s ISS governance QualityScore as of 31 July 2022 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.